Biotechnology company and global drug delivery platform
innovator Lexaria Bioscience
Corp. (CSE: LXX) (OTCQX: LXRP)today announced its receipt of a new patent
granted in Australia: #2016367037 / Grant Date August 15, 2019 – “Stable
ready-to-drink beverage compositions comprising lipophilic active agents.”
According to the update, this increases Lexaria’s portfolio to 16 awarded
patents protecting its DehydraTECH(TM) drug delivery platform, with eight in
the USA and eight in Australia. The new Australian patent, together with
Australian Patent #2016367036 announced on August 15, 2019, are the first
granted in Lexaria’s second and third patent families that differ from the
company’s original patent family, “Food and beverage compositions infused with
lipophilic active agents and methods of use thereof.” These new patents include
claims for DehydraTECH technology with respect to food and beverage use and
also, for the first time, for pharmaceutical applications for delivery of
cannabinoids as methods of treating certain conditions. These include, but are
not limited to heart disease, neurological diseases, obesity, metabolic and
appetite disorders, hepatic diseases, diabetes, cancer via chemotherapy,
irritable bowel syndrome (“IBS”), marijuana abuse, and opioid, alcohol,
nicotine or cocaine addiction.
To view the full press releases, visit http://ibn.fm/JemJa
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its
DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment